



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |                          |                        |               |
|---|---|----|--------------------------|------------------------|---------------|
| <b>Substitute for form 1449A/B/PTO</b><br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    | <b>Complete if Known</b> |                        |               |
|   |   |    | Application Number       | 10/699,635             |               |
|   |   |    | Filing Date              | October 30, 2003       |               |
|   |   |    | First Named Inventor     | William G. Tatton      |               |
|   |   |    | Art Unit                 | 1646                   |               |
|   |   |    | Examiner Name            | Not Yet Assigned       |               |
| Sheet   | 1 | of | 3                        | Attorney Docket Number | IFM-005CP4CN2 |

| U.S. PATENT DOCUMENTS |                          |  |                                   |  |   |
|-----------------------|--------------------------|--|-----------------------------------|--|---|
| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Document Number                          | Publication<br>Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|                       |                          | Number-Kind Code <sup>2</sup> (if known) |                                   |  |   |
| Z-F                   | A1                       | 4,861,800                                | 08-29-1989                        | Buyske   |   |
| Z-F                   | A2                       | 5,242,950                                | 09-07-1993                        | Fries Hastings                                     |   |
| Z-F                   | A3                       | 5,276,057                                | 01-04-1994                        | Milgram, et al.                                    |   |
| Z-F                   | A4                       | 5,322,859                                | 06-21-1994                        | Schoenwald, et al.                                 |   |
| Z-F                   | A5                       | 5,444,095                                | 08-22-1995                        | Tatton, et al.                                     |   |

| FOREIGN PATENT DOCUMENTS |                          |   |                                   |  |   |                |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner<br>Initials*    | Cite<br>No. <sup>1</sup> | Foreign Patent Document   | Publication<br>Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear | T <sup>6</sup> |
|                          |                          | Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known) |                                   |  |   |                |
| Z-F                      | A6                       | WO 85/05617 A1  | 12-19-1985                        | Chinoin Gyogyszer                                  |   |                |
| Z-F                      | A7                       | WO 88/04552 A1  | 06-30-1988                        | Chinoin Gyogyszer                                  |   |                |
| Z-F                      | A8                       | CA 1,329,132  | 12-09-1988                        | Somerset Pharmaceuticals                           |   |                |
| Z-F                      | A9                       | WO 90/01928 A1  | 03-08-1990                        | Chinoin Gyogyszer                                  |   |                |
| Z-F                      | A10                      | EP 0 473 252 A2   | 03-04-1992                        | Deprenyl Animal Health                             |   |                |
| Z-F                      | A11                      | WO 92/17169 A1  | 10-15-1992                        | University of Toronto                              |   |                |
| Z-F                      | A12                      | WO 92/21333 A2  | 12-10-1992                        | Pharmavene, Inc.                                   |   |                |
| Z-F                      | A13                      | WO 93/12775 A1  | 07-08-1993                        | Chinoin Gyogyszer                                  |   |                |
| Z-F                      | A14                      | WO 95/11016 A1  | 04-27-1995                        | Teva Pharmaceutical Ind.                           |   |                |
| Z-F                      | A15                      | WO 96/22068 A2  | 07-25-1996                        | Somerset Pharmaceuticals                           |   |                |
| Z-F                      | A16                      | WO 96/26720 A1  | 09-06-1996                        | R.P. Scherer Ltd.                                  |   |                |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS |                          |   |                |
|---------------------------------|--------------------------|---|----------------|
| Examiner<br>Initials            | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
| Z-F                             | A17                      | Ariens, E. "Stereochemistry: A Source of Problems in Medicinal Chemistry," <i>Medicinal Research Reviews</i> 6(4): 451-66 (1986)  |                |
| Z-F                             | A18                      | Birkmayer, W. et al. "Increased Life Expectancy Resulting from Addition of L-Deprenyl to Madopar® Treatment in Parkinson's Disease: A Longterm Study" <i>J. Neural Transmission</i> 64:113-127 (1985)   |                |
| Z-F                             | A19                      | Buys, Y.M. et al., "Deprenyl Rescues Retinal Ganglion Layer Cells After Optic Nerve Crush", <i>Investigative Ophthalmology &amp; Visual Science</i> 35(4):1484, Abstract No. 1062 (1994)  |                |

|                       |                    |                    |          |
|-----------------------|--------------------|--------------------|----------|
| Examiner<br>Signature | <i>Zachary Fay</i> | Date<br>Considered | 10/16/05 |
|-----------------------|--------------------|--------------------|----------|



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |                          |                        |               |
|--|---|----|--------------------------|------------------------|---------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    | <b>Complete if Known</b> |                        |               |
|  |   |    | Application Number       | 10/699,635             |               |
|  |   |    | Filing Date              | October 30, 2003       |               |
|  |   |    | First Named Inventor     | William G. Tatton      |               |
|  |   |    | Art Unit                 | 1646                   |               |
|  |   |    | Examiner Name            | Not Yet Assigned       |               |
| Sheet  | 2 | of | 3                        | Attorney Docket Number | IFM-005CP4CN2 |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials               | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
| 2.f                             | B1                    | Greenwood, Carol E. et al. "Increased Dopamine Synthesis in Aging Substantia Nigra Neurons" <i>Neurobiology of Aging</i> 12:557-565 (1991)  |                |
| 2.f                             | B2                    | Heinonen, E.H. "Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of MAO-B in Human Subjects" <i>Neurology</i> , A156, No. 19P (1993)   |                |
| 2.f                             | B3                    | Jonakait, G. Miller et al. "Development of serotonin, substance P and thyrotrophin-releasing hormone in mouse medullary raphe grown in organotypic tissue culture: developmental regulation by serotonin" <i>Brain Research</i> 473:336-343 (1988)              |                |
| 2.f                             | B4                    | Knoll, J. "The Facilitation of Dopaminergic Activity in the Aged Brain by (-)Deprenyl A Proposal for a Strategy to Improve the Quality of Life in Senescence" <i>Mechanisms of Aging and Development</i> 30:109-122 (1983)                                      |                |
| 2.f                             | B5                    | Magyar, K. "Behaviour of (-)-deprenyl and its analogues" <i>J. Neural Transm. Suppl.</i> 41:167-175 (1994)  |                |
| 2.f                             | B6                    | Mehra, K. et al. "Pargyline Drops in Glaucoma" <i>Arch Ophthalmol.</i> 92(6):453-454 (1974)   |                |
| 2.f                             | B7                    | The Merck Index, 10th edition, Windholz, M. (Ed.), Abstract 2893, p. 423, Abstract 6988, p. 1023, Abstract 1983; p. 282 (1983)  |                |
| 2.f                             | B8                    | Nickel, B. "Effect of selegiline and desmethyl-selegiline on cortical electric activity in rats" <i>J. Neural Transm. Suppl.</i> 32:139-144 (1990)  |                |
| 2.f                             | B9                    | Rao, T.S. "N,N-Dipropargyl-2-Phenylethylamine, A Potential Prodrug of 2-Phenylethylamine: Neurochemical and Neuropharmacological Studies in Rat" <i>Brain Research Bulletin</i> 19: 47-55 (1987)  |                |
| 2.f                             | B10                   | Riederer, P. and Youdim, M. "Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with (-)-Deprenyl" <i>Journal of Neurochemistry</i> 46:1359-65 (1986)   |                |
| 2.f                             | B11                   | Rinne, "Nigral degeneration in Parkinson's disease in relation to clinical features" <i>Acta Neurol Scand.</i> 84, Suppl. 136:87-90 (1991)  |                |
| 2.f                             | B12                   | Rinne, et al. "Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease" <i>Neurology</i> 41:859-861(1991)  |                |
| 2.f                             | B13                   | Seniuk et al. "Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP" <i>Brain Res.</i> 527(1):7-20 (1990)   |                |
| 2.f                             | B14                   | Tatton et al. "Interactions Between MPTP-Induced and Age-Related Neuronal Death in a Murine Model of Parkinson's Disease" <i>Can. J. Neurological Sciences</i> 19:124-133 (1992)  |                |
| 2.f                             | B15                   | Tatton et al. "Different Rates of Age-Related Loss For Four Murine Monoaminergic Neuronal Populations" <i>Neurobiol. of Aging</i> 12: 543-556 (1991)  |                |
| 2.f                             | B16                   | Tatton et al. "MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells" <i>Brain Res.</i> 527(1): 21-31(1990)  |                |

|                    |                   |                 |          |
|--------------------|-------------------|-----------------|----------|
| Examiner Signature | <i>Robert Foy</i> | Date Considered | 10/16/05 |
|--------------------|-------------------|-----------------|----------|



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |                          |                   |                        |               |
|---|---|--------------------------|-------------------|------------------------|---------------|
| <b>Substitute for form 1449A/B/PTO</b><br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   | <b>Complete if Known</b> |                   |                        |               |
|   |   | Application Number       | 10/699,635        |                        |               |
|   |   | Filing Date              | October 30, 2003  |                        |               |
|   |   | First Named Inventor     | William G. Tatton |                        |               |
|   |   | Art Unit                 | 1646              |                        |               |
|   |   | Examiner Name            | Not Yet Assigned  |                        |               |
| Sheet   | 3 | of                       | 3                 | Attorney Docket Number | IFM-005CP4CN2 |

| NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials               | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                                | T <sup>2</sup> |
| Z-f                             | C1                    | Timar, Julia "Recovery of Mao-B Enzyme Activity After (-)Deprenyl (Selegiline) Pretreatment, Measured In Vivo" <i>Acta Physiologica Hungarica</i> 74(3-4):259-266 (1989)   |                |
| Z-f                             | C2                    | Torok, Tamas L. et al. "Transmitter releasing action of selegiline ((-)-deprenyl) from peripheral sympathetic nerves under different experimental conditions" <i>J. Pharm. Pharmacol.</i> 39(10):797-802 (abstract of pp. 48 of Chemical Abstracts) (1987)                                     |                |
| Z-f                             | C3                    | Trope, G.Z. et al. "Deprenyl Improves Visual Function in Glaucoma Patients," <i>Investigative Ophthalmology &amp; Visual Science</i> 35(4):2178, Abstract No. 4270-40 (1994)   |                |
| Z-f                             | C4                    | Zsilla, Gabriella et al. "Neurochemical evidences for facilitation of dopaminergic function in rat brain by repeated doses of (-) deprenyl" <i>Dev. Neurosci. (Amsterdam; 17 (Regular Transm. Funct.: Basic Clin. Aspects))</i> ; Abstract of pp. 345-348; pp. 64 of Chemical Abstracts (1984) |                |
| Z-f                             | C5                    | Zsilla, Gabriella et al. "The Effect of Repeated Doses of (-) Deprenyl On The Dynamics of Monoaminergic Transmission. Comparison With Clorgyline" <i>Pol. J. Pharmacol. Pharm.</i> 38:57-67 (1986)   |                |
| Z-f                             | C6                    | Zsilla, Gabriella et al. "(-)-Deprenyl A Selective Mao 'B' Inhibitor Increases [ <sup>3</sup> H]imipramine Binding And Decreases $\beta$ -Adrenergic Receptor Function" <i>European J. of Pharmacol.</i> 89:111-117 (1983)   |                |
| Z-f                             | C7                    | Zsilla, G. and Knoll, J. "The Action of (-)Deprenyl on Monoamine Turnover Rate in Rat Brain" <i>Typical and Atypical Antidepressants: Molecular Mechanisms</i> pp. 211-217 (1982)  |                |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

|                    |                   |                 |          |
|--------------------|-------------------|-----------------|----------|
| Examiner Signature | <i>Zohrab Fay</i> | Date Considered | 10/16/05 |
|--------------------|-------------------|-----------------|----------|